Request Free Sample ×
GCC Chorea Market Research Report- Forecast To 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Chorea Market

ID: MRFR/HC/51943-HCR
200 Pages
Vikita Thakur
April 2026

GCC Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Chorea Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

GCC Chorea Market Summary

As per Market Research Future analysis, the GCC chorea market Size was estimated at 20.0 USD Million in 2024. The GCC chorea market is projected to grow from 21.27 USD Million in 2025 to 39.33 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.3% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The GCC chorea market is experiencing notable growth driven by increased awareness and advancements in treatment options.

  • Rising awareness and diagnosis of chorea disorders are significantly influencing market dynamics.
  • Advancements in treatment options are enhancing patient outcomes and expanding market potential.
  • The GCC region is witnessing a growing demand for personalized medicine, particularly in the largest segment of Huntington's disease.
  • Key market drivers include the increasing prevalence of chorea disorders and government initiatives supporting research and funding.

Market Size & Forecast

2024 Market Size 20.0 (USD Million)
2035 Market Size 39.33 (USD Million)
CAGR (2025 - 2035) 6.34%

Major Players

Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), Pfizer Inc (US), Eli Lilly and Company (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

GCC Chorea Market Trends

The chorea market in the GCC region is currently experiencing notable developments, driven by a combination of increasing awareness of neurological disorders and advancements in treatment options. The prevalence of chorea, often associated with conditions such as Huntington's disease, has prompted healthcare providers to enhance diagnostic capabilities and therapeutic interventions. As a result, there is a growing demand for specialized healthcare services and medications tailored to manage symptoms effectively. Furthermore, the integration of innovative technologies in treatment protocols appears to be reshaping patient care, potentially leading to improved outcomes. In addition, the regulatory landscape within the GCC is evolving, with governments prioritizing healthcare reforms that support research and development in neurology. This shift may foster collaborations between public and private sectors, encouraging investment in the chorea market. The increasing focus on personalized medicine and patient-centric approaches suggests a promising future for therapies that address the unique needs of individuals affected by chorea. Overall, the market is poised for growth, reflecting a commitment to enhancing the quality of life for patients and their families.

Rising Awareness and Diagnosis

There is a noticeable increase in awareness regarding chorea and its associated conditions within the GCC. This heightened understanding among healthcare professionals and the general public is leading to improved diagnostic practices. As a result, more individuals are being identified and treated for chorea, which is likely to drive demand for specialized healthcare services.

Advancements in Treatment Options

The chorea market is witnessing significant advancements in treatment methodologies. Innovative therapies, including pharmacological interventions and supportive care strategies, are being developed to better manage symptoms. This trend indicates a shift towards more effective and personalized treatment plans, enhancing patient outcomes.

Regulatory Support for Research

Governments in the GCC are increasingly supporting research initiatives focused on neurological disorders, including chorea. This regulatory backing is expected to facilitate collaborations between academic institutions and healthcare providers, potentially leading to breakthroughs in treatment and management strategies.

GCC Chorea Market Drivers

Rising Healthcare Expenditure

The increase in healthcare expenditure across the GCC is a crucial factor influencing the chorea market. Governments in the region are investing heavily in healthcare infrastructure, with budgets for health services growing by approximately 10-15% annually. This financial commitment is aimed at improving access to care and enhancing treatment options for various disorders, including chorea. As healthcare spending rises, there is a corresponding increase in the availability of advanced therapies and diagnostic tools. This trend is likely to attract more patients seeking effective management of chorea disorders, thereby driving market growth. Additionally, the expansion of health insurance coverage in the GCC may further facilitate access to necessary treatments, contributing to a more favorable environment for the chorea market.

Government Initiatives and Funding

Government initiatives aimed at improving healthcare infrastructure and funding for neurological research are pivotal for the chorea market. In the GCC, various health ministries are prioritizing the establishment of specialized centers for neurological disorders, which include chorea. Increased funding for research projects is also evident, with allocations reaching millions of $ annually. These initiatives not only enhance the quality of care for patients but also encourage pharmaceutical companies to invest in the development of new treatments. As a result, the chorea market is likely to benefit from a more robust research environment, leading to the introduction of innovative therapies and improved patient management strategies.

Technological Innovations in Treatment

Technological advancements in the development of therapies for chorea disorders are significantly influencing the chorea market. Innovations such as gene therapy and advanced pharmacological treatments are emerging as potential solutions. For instance, the introduction of novel medications targeting specific pathways in chorea has shown promise in clinical trials, potentially improving patient outcomes. The GCC region is witnessing a surge in research initiatives aimed at harnessing these technologies, with investments in biotechnology and pharmaceutical sectors increasing. This trend is likely to enhance the availability of effective treatments, thereby attracting more patients and healthcare providers to the chorea market. As a result, the market may experience substantial growth, driven by the demand for cutting-edge therapeutic options.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is emerging as a significant driver in the chorea market. Patients are increasingly seeking tailored treatment options that consider their unique genetic and phenotypic profiles. This trend is particularly relevant in the GCC, where healthcare providers are beginning to adopt precision medicine approaches. The integration of genetic testing and biomarker identification into treatment plans for chorea disorders may enhance therapeutic efficacy and minimize adverse effects. As healthcare systems in the region evolve, the demand for personalized therapies is expected to rise, potentially reshaping the landscape of the chorea market. This shift could lead to increased collaboration between researchers, clinicians, and pharmaceutical companies to develop customized treatment regimens.

Increasing Prevalence of Chorea Disorders

The rising incidence of chorea disorders in the GCC region is a notable driver for the chorea market. Factors such as genetic predispositions and environmental influences contribute to this increase. Recent studies indicate that the prevalence of Huntington's disease, a primary cause of chorea, is estimated to affect approximately 5-10 individuals per 100,000 in the GCC. This growing patient population necessitates enhanced healthcare services and treatment options, thereby stimulating market growth. As awareness of these disorders expands, healthcare providers are more likely to seek innovative therapies, which could lead to a more competitive landscape in the chorea market. Furthermore, the increasing burden on healthcare systems may prompt governments to allocate more resources towards research and development, ultimately benefiting the market.

Market Segment Insights

By Type: Huntington's disease (Largest) vs. Drug-induced Chorea (Fastest-Growing)

In the GCC chorea market, the segment distribution shows that Huntington's disease holds the largest share due to its widespread recognition and established treatment protocols. It remains the dominant type, largely attributed to the growing awareness and diagnosis rates across the region. On the other hand, Drug-induced Chorea represents a rapidly growing segment as more awareness around medication-related side effects emerges and as healthcare providers increasingly diagnose these cases, thus contributing to a dynamic market landscape. The growth trends for these segments are influenced by various factors. Huntington's disease benefits from robust clinical research and ongoing developments in therapy options, while Drug-induced Chorea is seeing accelerated growth driven by advances in pharmacovigilance and the rise in polypharmacy practices. Moreover, increased education about chorea symptoms among healthcare professionals enhances the identification and treatment of these conditions, fostering market expansion for both segments.

Huntington's disease (Dominant) vs. Drug-induced Chorea (Emerging)

Huntington's disease is recognized as the dominant segment within the GCC chorea market due to its established presence and extensive research investments focused on its treatment. This form of chorea is hereditary, and its management requires specialized care, making it a focal point for healthcare providers. Conversely, Drug-induced Chorea is emerging as a significant player, primarily driven by the rising incidence of drug reactions among patients taking multiple medications. This segment is characterized by the challenges in identifying causative agents, making awareness and education crucial for proper diagnosis and management. As a result, both segments reflect distinct needs in patient care and treatment pathways.

By Treatment: Surgical care (Largest) vs. Medical care (Fastest-Growing)

In the GCC chorea market, the segment distribution shows a clear preference towards surgical care, which holds a dominant share among treatment options. This trend is indicative of the healthcare system's capacity to manage more complex cases and the increasing availability of specialized surgical facilities. Conversely, medical care represents a smaller yet rapidly growing segment, attracting attention for its potential in early intervention and management of chorea symptoms. Looking ahead, the growth trends for surgical care are driven by advances in technology and increased surgical proficiency among healthcare professionals. On the other hand, medical care is emerging as a crucial area, particularly with new pharmacological treatments that promise better symptom management. The emphasis on patient-centered care and the shift towards non-invasive treatment options further contribute to the expansion of this segment.

Surgical care: Dominant vs. Medical care: Emerging

Surgical care in the GCC chorea market has established itself as the dominant treatment option, characterized by its ability to address severe cases and provide definitive solutions. Its prominence is bolstered by an increasing number of specialized surgical centers and advanced surgical techniques. In contrast, medical care is an emerging segment, focusing on pharmacological therapies and other non-invasive treatment options. This segment is gaining traction as healthcare providers recognize the importance of early diagnosis and disease management. The shift towards personalized medicine and patient-centered approaches enhances its appeal, positioning medical care as a flexible and innovative alternative for patients seeking multiple management strategies.

By Distribution Channel: Hospitals (Largest) vs. Drug Stores (Fastest-Growing)

In the GCC chorea market, hospitals represent the largest distribution channel, commanding a significant share due to their ability to provide comprehensive treatment options. Clinics and diagnostic centers also contribute notably, although they capture a smaller percentage of the market. Pharmacies and drug stores have emerged as essential players, particularly in urban areas, offering accessible care and treatment solutions. This distribution reflects the demographic trends and patient preferences in the region, as consumers seek convenience and quality healthcare options. The growth trends in the distribution channel segment are driven by increasing healthcare expenditure and a rise in chronic diseases in the region. Drug stores are becoming the fastest-growing segment as they enhance their product offerings and extend operating hours to meet consumer needs. Additionally, the expansion of telemedicine and online pharmacy services is expected to influence growth, as they provide consumers with more options and greater convenience in accessing resources.

Hospitals (Dominant) vs. Drug Stores (Emerging)

Hospitals serve as the dominant force in the GCC chorea market's distribution channels, characterized by their extensive medical facilities and specialized services. They provide a comprehensive range of healthcare services, which is crucial for patients requiring complex treatment. Conversely, drug stores represent an emerging segment gaining traction due to their focus on convenience and accessibility, particularly in urban areas where foot traffic is high. This segment is increasingly adapting to consumer needs by expanding product lines and offering health consultations. Both segments play critical roles in patient care, with hospitals focused on intensive care solutions and drug stores catering to everyday pharmaceutical needs.

By Symptoms: Involuntary muscle movements (Largest) vs. Speech problems (Fastest-Growing)

In the GCC chorea market, the distribution of market share among the symptoms segment reveals that involuntary muscle movements hold a significant portion, marking it as the largest segment within this category. This group encompasses an array of involuntary movements, which are key indicators of the condition, and has garnered substantial attention in both diagnostics and treatment approaches, leading to its prominent market position. Conversely, speech problems, while smaller in overall market share, are identified as the fastest-growing segment due to increasing awareness and advancements in therapeutic interventions. The surge in demand for effective communication strategies and rehabilitation services is driving growth in this area, reflecting a shifting focus towards comprehensive patient care and quality of life improvements.

Involuntary muscle movements: Dominant vs. Speech problems: Emerging

Involuntary muscle movements are characterized by uncontrolled, spontaneous actions that significantly affect patients' daily lives and social interactions. As the dominant segment in the GCC chorea market, these movements are often the first symptoms to be recognized, leading to prompt diagnosis and intervention. This symptom's complexity encourages extensive research and development of targeted therapies, solidifying its stronghold in the market. On the other hand, speech problems, categorized as an emerging segment, represent a growing area of concern for caregivers and healthcare professionals. These issues can impede communication, often leading to social isolation. As awareness surrounding the importance of addressing speech issues increases, innovative therapeutic techniques and solutions are being developed, enhancing this segment's attractiveness and growth potential in the market.

By End-Users: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the GCC chorea market, the distribution of market share among end-users indicates a strong dominance of hospitals, which comprise a significant portion of the market. Clinics also represent a noteworthy share, but their impact is lesser compared to hospitals. Ambulatory surgical centers, while smaller in market share, show potential as they continue to gain traction among healthcare providers, driven by their convenience and efficiency in managing patient care. The growth trends within the end-user segment reveal that hospitals are continuously expanding their services and capabilities to integrate new treatments for chorea, contributing to their dominant market position. Meanwhile, ambulatory surgical centers are emerging rapidly due to a shift towards outpatient care options, driven by advances in technology and patient preference for less invasive procedures, showcasing them as the fastest-growing segment in the market.

Clinics (Dominant) vs. Others (Emerging)

Clinics in the GCC chorea market hold a dominant position, serving as the first point of contact for many patients seeking treatment for chorea. They are crucial in providing preliminary assessments and managing early-stage symptoms. On the other hand, the 'Others' category represents an emerging segment that includes various specialized facilities and alternative treatment centers. This segment is beginning to gain recognition as innovative therapies and supportive care options proliferate, driven by advancements in medical technology and a growing inquiry into integrated care approaches. Both segments are essential in creating a comprehensive healthcare framework to address the diverse needs of patients with chorea.

Chorea Market Treatment Insights

Chorea Market Treatment Insights

The Treatment segment within the GCC Chorea Market focuses on addressing the symptoms and underlying causes of chorea through various modalities. Medical care is pivotal, encompassing pharmacological interventions aimed at symptom management and improving the quality of life for patients suffering from chorea. In contrast, surgical care may be considered for severe cases where traditional medical treatments are ineffective, emphasizing neuro-modulatory techniques to alleviate movements. 

The significance of this segment lies in its ability to cater to the diverse needs of patients, ensuring tailored solutions that enhance patient outcomes.Given the rising awareness of neurological disorders in the GCC region, along with concerted efforts by health authorities to improve chronic disease management, the Treatment segment is expected to gain momentum. The growing aging population, increasing incidences of genetic disorders associated with chorea, and enhanced healthcare infrastructure in the GCC region serve as robust growth drivers. However, challenges such as access to advanced therapies and the need for skilled healthcare professionals persist.

Nevertheless, opportunities abound for innovation and improvement in treatment strategies, driven by ongoing Research and Development efforts in the region.Overall, the Treatment segment is positioned to play a crucial role in the advancement of care for chorea within the GCC Chorea Market.

Get more detailed insights about GCC Chorea Market
Request Free Sample

Key Players and Competitive Insights

The chorea market exhibits a competitive landscape characterized by a blend of innovation and strategic partnerships among key players. Major companies such as Teva Pharmaceutical Industries Ltd (IL), AbbVie Inc (US), and Novartis AG (CH) are actively shaping the market dynamics. Teva (IL) focuses on expanding its portfolio through strategic acquisitions and partnerships, which enhances its product offerings in the chorea segment. AbbVie (US) emphasizes research and development, particularly in novel therapies, positioning itself as a leader in innovative treatment solutions. Meanwhile, Novartis (CH) is leveraging digital transformation to optimize its operations and improve patient engagement, thereby enhancing its competitive edge. Collectively, these strategies foster a dynamic environment where innovation and collaboration are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they drive advancements in treatment options and patient care, thereby shaping the overall competitive landscape.

In October Teva Pharmaceutical Industries Ltd (IL) announced a strategic partnership with a leading biotechnology firm to co-develop a new treatment for chorea. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, reflecting Teva's commitment to innovation and patient-centric solutions. The partnership may also strengthen Teva's market position by expanding its research capabilities and access to cutting-edge technologies.

In September AbbVie Inc (US) launched a new clinical trial for a groundbreaking therapy aimed at chorea management. This initiative underscores AbbVie's focus on advancing treatment modalities through rigorous research. The trial's outcomes could potentially redefine treatment protocols and solidify AbbVie's reputation as a pioneer in the field, thereby enhancing its competitive standing.

In August Novartis AG (CH) unveiled a digital health platform designed to support patients with chorea. This platform integrates telehealth services and personalized treatment plans, reflecting Novartis's commitment to leveraging technology for improved patient outcomes. The introduction of such a platform may not only enhance patient engagement but also position Novartis as a forward-thinking leader in the chorea market.

As of November current trends in the chorea market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is likely to evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies will need to prioritize research and development, alongside strategic partnerships, to maintain a competitive edge in the market.

Key Companies in the GCC Chorea Market include

Industry Developments

The GCC Chorea Market is witnessing significant activity, with notable developments surrounding key pharmaceutical companies. Alnylam Pharmaceuticals has been expanding its presence in the region, particularly in the treatment of genetic disorders related to Chorea. In recent months, Teva Pharmaceutical Industries has collaborated with local entities to enhance access to medication, indicating a trend toward localized distribution. 

Current affairs show an increasing emphasis on Research and Development as Bristol-Myers Squibb and Pfizer invest heavily in innovative therapies targeting neurological conditions, including Chorea. Meanwhile, Sage Therapeutics and Neurocrine Biosciences are exploring potential partnerships focused on developing novel treatment options. There have been discussions regarding mergers and acquisitions, particularly in October 2023, when Eisai entered into a strategic alliance with Acorda Therapeutics to jointly develop therapies in the GCC region. 

The market is also experiencing growth, evidenced by Horizon Therapeutics' recent report of a significant revenue increase attributed to its Chorea treatment portfolio. Regulatory bodies in the GCC are advocating for improved healthcare infrastructure to support the prescription of new therapies, fostering a favorable environment for these companies. The last two to three years have seen a push for better patient access to medication and treatment options by various stakeholders in the GCC.

Future Outlook

GCC Chorea Market Future Outlook

The Chorea Market is projected to grow at a 6.34% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare investments.

New opportunities lie in:

  • Development of telehealth platforms for remote patient monitoring
  • Investment in innovative drug delivery systems for chorea treatments
  • Expansion of specialized rehabilitation centers focusing on chorea management

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased healthcare focus.

Market Segmentation

GCC Chorea Market Type Outlook

  • Huntington's disease
  • Rheumatic (Sydenham's Chorea)
  • Drug-induced Chorea

GCC Chorea Market Symptoms Outlook

  • Involuntary muscle movements
  • Milkmaid's grip
  • Speech problems
  • Seizures

GCC Chorea Market End-Users Outlook

  • Clinics
  • Hospitals
  • Ambulatory surgical centers
  • Others

GCC Chorea Market Treatment Outlook

  • Medical care
  • Surgical care

GCC Chorea Market Distribution Channel Outlook

  • Hospitals
  • Clinics
  • Diagnostic centers
  • Drug stores
  • Pharmacies
  • Others

Report Scope

MARKET SIZE 2024 20.0(USD Million)
MARKET SIZE 2025 21.27(USD Million)
MARKET SIZE 2035 39.33(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.34% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), Pfizer Inc (US), Eli Lilly and Company (US)
Segments Covered Type, Treatment, Distribution Channel, Symptoms, End-Users
Key Market Opportunities Emerging therapies and technologies addressing unmet needs in the chorea market present substantial growth potential.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the GCC chorea market.
Countries Covered GCC
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

FAQs

What was the overall market valuation of the GCC chorea market in 2024?

The overall market valuation was $20.0 Million in 2024.

What is the projected market valuation for the GCC chorea market by 2035?

The projected valuation for 2035 is $39.33 Million.

What is the expected CAGR for the GCC chorea market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 6.34%.

Which companies are considered key players in the GCC chorea market?

Key players include Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Roche Holding AG, Sanofi S.A., Pfizer Inc, and Eli Lilly and Company.

What are the market segments for the GCC chorea market based on type?

Market segments based on type include Huntington's disease, Rheumatic (Sydenham's Chorea), and Drug-induced Chorea.

What were the valuations for Huntington's disease and Rheumatic Chorea in 2024?

Huntington's disease had a valuation of $8.0 Million to $15.0 Million, while Rheumatic Chorea ranged from $6.0 Million to $12.0 Million.

What treatment segments are included in the GCC chorea market?

Treatment segments include Medical care and Surgical care.

What is the distribution channel breakdown for the GCC chorea market?

Distribution channels include Hospitals, Clinics, Diagnostic centers, Drug stores, Pharmacies, and Others.

What symptoms are associated with chorea in the GCC market?

Symptoms include involuntary muscle movements, Milkmaid's grip, speech problems, and seizures.

What are the end-user segments in the GCC chorea market?

End-user segments include Clinics, Hospitals, Ambulatory surgical centers, and Others.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓